Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $7.00 | Buy | H.C. Wainwright |
| 4/24/2024 | $8.00 | Buy | Craig Hallum |
| 6/22/2023 | $7.00 | Perform → Outperform | Oppenheimer |
| 6/30/2021 | $38.00 → $32.00 | Buy | Roth Capital |
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00
Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00
Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00
SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf
Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has issued approval to proceed with the planned two-part Phase 2 study, which will be conducted as an investigator-sponsored trial at Tygerberg Hospital
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment Conference, September 9-11, New York – Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and participate in one-on-one meetings. Lake Street Best Ideas Growth Conference Big 8, September 12, New York – Management will participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting
8-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)
10-Q - DiaMedica Therapeutics Inc. (0001401040) (Filer)
EFFECT - DiaMedica Therapeutics Inc. (0001401040) (Filer)
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralWhite Paper: The Potential of DM199 to Treat PreeclampsiaDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.
- SEC Filing
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf
Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, A
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2024 financial results will be released after the markets close on Wednesday, August 7th. DiaMedica will host a live conference call on Thursday, August 8th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, August 8, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/RzlwnM9ne8E Dial In: (646) 357-8785 Conference
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic
Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was